Index RUT P/E - EPS (ttm) -3.35 Insider Own 25.68% Shs Outstand 102.32M Perf Week 0.25%
Market Cap 1.37B Forward P/E - EPS next Y -3.69 Insider Trans -2.30% Shs Float 84.07M Perf Month -13.65%
Income -317.42M PEG - EPS next Q -0.85 Inst Own 81.00% Short Float 13.88% Perf Quarter -53.82%
Sales 0.00M P/S - EPS this Y -5.63% Inst Trans 4.13% Short Ratio 5.81 Perf Half Y -64.82%
Book/sh 6.16 P/B 1.96 EPS next Y -3.77% ROA -74.14% Short Interest 11.67M Perf Year -56.10%
Cash/sh 5.68 P/C 2.13 EPS next 5Y 4.20% ROE -88.03% 52W Range 11.18 - 47.45 Perf YTD -48.73%
Dividend Est. - P/FCF - EPS past 5Y -59.45% ROI -48.91% 52W High -74.54% Beta 1.14
Dividend TTM - Quick Ratio 15.60 Sales past 5Y 0.00% Gross Margin - 52W Low 8.05% ATR (14) 0.80
Dividend Ex-Date - Current Ratio 15.60 EPS Y/Y TTM 14.93% Oper. Margin - RSI (14) 39.47 Volatility 5.47% 6.34%
Employees 191 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin - Recom 1.21 Target Price 48.21
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q 19.38% Payout - Rel Volume 1.16 Prev Close 12.26
Sales Surprise - EPS Surprise 6.03% Sales Q/Q - Earnings Feb 27 BMO Avg Volume 2.01M Price 12.08
SMA20 -3.43% SMA50 -12.58% SMA200 -58.53% Trades
Volume 2,328,131 Change -1.47%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-12-25 Initiated BMO Capital Markets
Outperform
$50
Mar-07-25 Initiated Scotiabank
Sector Outperform
$50
Dec-13-24 Initiated Robert W. Baird
Outperform
$46
Nov-26-24 Initiated RBC Capital Mkts
Outperform
$45
Oct-24-24 Downgrade JP Morgan
Overweight → Neutral
$43 → $35
May-21-24 Reiterated Chardan Capital Markets
Buy
$31 → $42
Apr-30-24 Initiated Morgan Stanley
Overweight
$40
Feb-20-24 Initiated H.C. Wainwright
Buy
$36
Feb-27-23 Upgrade Raymond James
Outperform → Strong Buy
$16 → $27
Feb-15-23 Initiated Oppenheimer
Outperform
$34
Jan-26-23 Initiated Guggenheim
Buy
$33
Jul-20-22 Initiated Chardan Capital Markets
Buy
$17
Jul-12-22 Initiated Raymond James
Outperform
$15
Oct-12-20 Initiated Stifel
Buy
$29
Oct-12-20 Initiated Piper Sandler
Overweight
$34
Oct-12-20 Initiated JP Morgan
Overweight
$27
Oct-12-20 Initiated Jefferies
Buy
$47
Show Previous Ratings
Mar-20-25 04:30PM
04:19PM
04:10PM
Mar-16-25 07:00PM
Mar-12-25 03:05PM
01:12PM
Loading…
01:12PM
Mar-11-25 07:30AM
Feb-27-25 07:30AM
Feb-14-25 04:05PM
Feb-13-25 09:35AM
Feb-06-25 09:39AM
Feb-03-25 07:30AM
Jan-28-25 09:35AM
Jan-21-25 07:30AM
Jan-10-25 06:30AM
07:30AM
Loading…
Jan-09-25 07:30AM
Jan-08-25 04:05PM
Nov-22-24 06:43AM
Nov-12-24 07:30AM
Nov-07-24 04:15PM
Oct-09-24 07:30AM
Oct-07-24 05:32PM
Sep-23-24 08:56AM
Sep-04-24 09:10AM
(Investor's Business Daily) +5.70%
08:15AM
Sep-03-24 12:37PM
06:31AM
06:30AM
Aug-29-24 07:30AM
Aug-12-24 10:52PM
05:10PM
Loading…
05:10PM
Jul-29-24 08:50AM
Jul-18-24 12:00PM
Jul-12-24 08:50AM
Jun-24-24 07:30AM
Jun-13-24 04:40PM
Jun-04-24 06:00AM
May-30-24 07:30AM
May-28-24 07:30AM
May-21-24 08:39PM
12:27PM
07:17AM
May-20-24 05:53PM
04:27PM
04:07PM
(Investor's Business Daily)
04:01PM
11:22AM
09:40AM
09:12AM
08:02AM
07:47AM
07:36AM
06:30AM
May-19-24 08:00AM
May-04-24 05:31AM
May-02-24 11:52PM
04:10PM
Apr-30-24 07:32AM
Mar-27-24 04:05PM
08:30AM
Mar-25-24 12:28PM
(Associated Press Finance) -7.72%
07:30AM
Mar-13-24 07:30AM
Mar-07-24 01:19PM
Mar-05-24 10:53AM
07:30AM
Mar-02-24 12:00AM
Feb-29-24 03:02AM
Feb-14-24 04:15PM
Feb-01-24 07:30AM
Jan-26-24 11:01PM
Jan-22-24 10:14PM
Jan-12-24 01:12PM
Jan-11-24 04:05PM
Jan-05-24 09:02AM
07:30AM
Jan-04-24 10:46PM
04:37PM
12:39PM
Jan-03-24 04:25PM
02:46PM
(The Wall Street Journal)
02:01PM
(The Wall Street Journal)
08:19AM
06:30AM
Jan-02-24 04:05PM
Nov-13-23 06:59PM
Nov-07-23 07:30AM
Oct-31-23 05:36AM
01:11AM
Oct-30-23 07:30AM
Sep-28-23 07:30AM
Sep-20-23 04:05PM
Sep-15-23 01:52PM
Sep-14-23 01:22PM
Sep-05-23 07:30AM
Aug-28-23 10:22AM
Aug-03-23 07:30AM
Jun-16-23 08:46AM
Jun-01-23 07:30AM
May-25-23 07:30AM
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Friedl-Naderer Johanna Chief Commercial Officer Mar 13 '25 Sale 12.12 143 1,733 96,057 Mar 13 04:13 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 11 '25 Sale 11.38 1,343 15,283 122,330 Mar 13 04:08 PM Beskrovnaya Oxana Chief Scientific Officer Mar 11 '25 Sale 11.38 2,153 24,501 195,840 Mar 13 04:08 PM Beskrovnaya Oxana Officer Mar 11 '25 Proposed Sale 11.38 2,153 24,493 Mar 11 04:09 PM Scalzo Richard William Officer Mar 11 '25 Proposed Sale 11.38 1,343 15,278 Mar 11 04:08 PM Kerr Douglas Chief Medical Officer Mar 05 '25 Sale 11.83 1,343 15,888 94,157 Mar 07 04:08 PM Cox John CEO & President Mar 05 '25 Sale 11.83 4,061 48,042 146,239 Mar 07 04:07 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 05 '25 Sale 11.83 917 10,848 123,673 Mar 07 04:06 PM Beskrovnaya Oxana Chief Scientific Officer Mar 05 '25 Sale 11.83 1,094 12,942 197,993 Mar 07 04:04 PM Kerr Douglas Officer Mar 05 '25 Proposed Sale 11.89 1,343 15,968 Mar 05 04:10 PM Cox John Officer Mar 05 '25 Proposed Sale 11.89 4,067 48,356 Mar 05 04:09 PM Beskrovnaya Oxana Officer Mar 05 '25 Proposed Sale 11.89 1,094 13,007 Mar 05 04:08 PM Scalzo Richard William Officer Mar 05 '25 Proposed Sale 11.89 915 10,879 Mar 05 04:07 PM Beskrovnaya Oxana Chief Scientific Officer Feb 18 '25 Sale 13.95 2,598 36,242 199,087 Feb 25 05:09 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 18 '25 Sale 13.95 2,488 34,708 124,590 Feb 18 05:09 PM Scalzo Richard William Officer Feb 18 '25 Proposed Sale 13.91 2,488 34,608 Feb 18 04:15 PM Beskrovnaya Oxana Officer Feb 18 '25 Proposed Sale 13.91 2,598 36,138 Feb 18 04:14 PM Beskrovnaya Oxana Chief Scientific Officer Dec 11 '24 Sale 28.12 2,334 65,632 201,685 Dec 11 08:41 PM Scalzo Richard William SVP, Head of Finance & Admin. Dec 11 '24 Sale 28.12 1,455 40,915 127,078 Dec 11 08:40 PM HIGH SUSANNA GATTI Officer Dec 11 '24 Proposed Sale 28.33 5,270 149,299 Dec 11 04:20 PM Beskrovnaya Oxana Officer Dec 11 '24 Proposed Sale 28.33 2,334 66,122 Dec 11 04:19 PM Scalzo Richard William Officer Dec 11 '24 Proposed Sale 28.33 1,455 41,220 Dec 11 04:18 PM Kersten Dirk Director Dec 06 '24 Sale 29.34 101,675 2,983,144 5,434,982 Dec 10 04:05 PM Kersten Dirk Director Dec 09 '24 Sale 29.18 34,437 1,004,872 5,400,545 Dec 10 04:05 PM Kersten Dirk Director Dec 04 '24 Sale 29.39 135,039 3,968,796 5,540,463 Dec 06 04:05 PM Kersten Dirk Director Dec 05 '24 Sale 29.05 3,806 110,564 5,536,657 Dec 06 04:05 PM Kersten Dirk Director Dec 02 '24 Sale 29.67 81,201 2,409,294 5,705,234 Dec 04 04:05 PM Kersten Dirk Director Dec 03 '24 Sale 29.05 29,732 863,715 5,675,502 Dec 04 04:05 PM McNeill Jonathan Officer Nov 25 '24 Proposed Sale 29.69 19,987 593,414 Nov 25 04:11 PM Forbion Capital Fund IV Cooper Affiliate Nov 22 '24 Proposed Sale 30.00 62,301 1,869,030 Nov 22 04:06 PM Incerti Carlo Director Nov 18 '24 Option Exercise 8.69 16,500 143,385 16,500 Nov 18 07:42 PM Incerti Carlo Director Nov 18 '24 Sale 28.73 16,500 474,045 0 Nov 18 07:42 PM Rhodes Jason P Director Nov 14 '24 Sale 33.10 782 25,884 15,962 Nov 18 05:31 PM Incerti Carlo Director Nov 18 '24 Proposed Sale 28.00 16,500 462,000 Nov 18 04:40 PM Scalzo Richard William SVP, Head of Finance & Admin. Nov 18 '24 Sale 28.20 2,735 77,127 95,833 Nov 18 04:28 PM Beskrovnaya Oxana Chief Scientific Officer Nov 18 '24 Sale 28.20 2,856 80,539 137,519 Nov 18 04:28 PM Farwell Wildon Officer Nov 18 '24 Proposed Sale 28.39 2,515 71,400 Nov 18 04:13 PM Scalzo Richard William Officer Nov 18 '24 Proposed Sale 28.39 2,735 77,646 Nov 18 04:10 PM Beskrovnaya Oxana Officer Nov 18 '24 Proposed Sale 28.39 2,856 81,081 Nov 18 04:06 PM McNeill Jonathan Officer Nov 18 '24 Proposed Sale 28.39 2,658 75,460 Nov 18 04:05 PM HIGH SUSANNA GATTI Officer Nov 18 '24 Proposed Sale 28.39 2,892 82,103 Nov 18 04:04 PM Kersten Dirk Director Nov 13 '24 Sale 35.24 10,803 380,698 62,301 Nov 15 04:05 PM Kersten Dirk Director Nov 14 '24 Sale 32.82 8,929 293,050 5,786,435 Nov 15 04:05 PM ForDyne B.V. Affiliate Nov 14 '24 Proposed Sale 32.83 1,500,000 49,250,000 Nov 14 04:59 PM Kersten Dirk Director Oct 18 '24 Sale 35.16 13,414 471,636 73,225 Oct 22 04:05 PM Kersten Dirk Director Oct 21 '24 Sale 35.06 121 4,242 73,104 Oct 22 04:05 PM Kersten Dirk Director Oct 16 '24 Sale 35.35 23,671 836,770 99,652 Oct 18 04:05 PM Kersten Dirk Director Oct 17 '24 Sale 35.17 13,013 457,667 86,639 Oct 18 04:05 PM Kersten Dirk Director Oct 02 '24 Sale 35.38 21,518 761,307 128,764 Oct 03 04:05 PM Kersten Dirk Director Oct 01 '24 Sale 35.16 8,423 296,153 150,282 Oct 03 04:05 PM Kersten Dirk Director Sep 30 '24 Sale 35.50 30,942 1,098,577 158,705 Oct 01 04:05 PM Kersten Dirk Director Sep 27 '24 Sale 35.00 32 1,120 189,647 Oct 01 04:05 PM Kersten Dirk Director Sep 25 '24 Sale 35.06 2,357 82,636 190,939 Sep 27 04:05 PM Kersten Dirk Director Sep 26 '24 Sale 35.29 1,260 44,465 189,679 Sep 27 04:05 PM Kersten Dirk Director Sep 20 '24 Sale 36.45 79,411 2,894,795 234,127 Sep 24 04:05 PM Kersten Dirk Director Sep 23 '24 Sale 35.32 40,831 1,442,098 193,296 Sep 24 04:05 PM Kersten Dirk Director Sep 19 '24 Sale 36.17 78,739 2,848,283 313,538 Sep 20 04:05 PM Kersten Dirk Director Sep 18 '24 Sale 35.03 1,554 54,437 392,277 Sep 20 04:05 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 18 '24 Sale 34.41 8,976 308,864 131,636 Sep 19 04:52 PM Scalzo Richard William SVP, Head of Finance & Admin. Sep 18 '24 Sale 34.55 1,390 48,024 98,568 Sep 19 04:52 PM Beskrovnaya Oxana Chief Scientific Officer Sep 18 '24 Sale 34.55 2,339 80,812 140,375 Sep 19 04:51 PM Scalzo Richard William Officer Sep 18 '24 Proposed Sale 34.51 1,390 47,964 Sep 18 04:24 PM Beskrovnaya Oxana Officer Sep 18 '24 Proposed Sale 34.51 2,339 80,715 Sep 18 04:23 PM McNeill Jonathan Officer Sep 18 '24 Proposed Sale 34.51 1,870 64,528 Sep 18 04:21 PM HIGH SUSANNA GATTI Officer Sep 18 '24 Proposed Sale 34.41 8,967 308,512 Sep 18 04:20 PM Kersten Dirk Director Sep 17 '24 Sale 35.13 3,272 114,945 393,831 Sep 18 04:05 PM Kersten Dirk Director Sep 16 '24 Sale 35.04 1,320 46,253 397,103 Sep 18 04:05 PM Farwell Wildon Officer Sep 11 '24 Proposed Sale 32.43 2,645 85,777 Sep 11 04:36 PM HIGH SUSANNA GATTI Officer Sep 11 '24 Proposed Sale 32.43 5,270 170,906 Sep 11 04:34 PM Scalzo Richard William Officer Sep 11 '24 Proposed Sale 32.43 1,468 47,607 Sep 11 04:31 PM Beskrovnaya Oxana Officer Sep 11 '24 Proposed Sale 32.43 2,161 70,081 Sep 11 04:28 PM McNeill Jonathan Officer Sep 11 '24 Proposed Sale 32.43 1,823 59,120 Sep 11 04:26 PM Beskrovnaya Oxana Chief Scientific Officer Sep 11 '24 Sale 31.89 2,161 68,914 142,714 Sep 11 04:13 PM Scalzo Richard William SVP, Head of Finance & Admin. Sep 11 '24 Sale 31.89 1,468 46,815 99,958 Sep 11 04:13 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 11 '24 Sale 31.89 5,270 168,060 140,612 Sep 11 04:13 PM Scalzo Richard William SVP, Head of Finance & Admin. Sep 06 '24 Option Exercise 12.56 116,478 1,463,376 227,500 Sep 10 04:05 PM Scalzo Richard William SVP, Head of Finance & Admin. Sep 06 '24 Sale 32.15 126,074 4,052,851 101,426 Sep 10 04:05 PM Kersten Dirk Director Sep 05 '24 Sale 35.03 1,577 55,242 398,423 Sep 09 04:05 PM Scalzo Richard William Officer Aug 19 '24 Proposed Sale 33.65 126,073 4,242,356 Sep 06 04:22 PM McNeill Jonathan Officer Sep 05 '24 Proposed Sale 33.61 166,767 5,605,442 Sep 05 04:34 PM Cox John CEO & President Sep 04 '24 Buy 33.04 32,000 1,057,216 8,000 Sep 04 05:42 PM Kersten Dirk Director Aug 30 '24 Sale 45.59 31,300 1,427,063 400,000 Sep 04 04:05 PM Kersten Dirk Director Aug 28 '24 Sale 44.83 77,853 3,490,029 487,708 Aug 30 04:05 PM Kersten Dirk Director Aug 29 '24 Sale 45.31 56,408 2,555,754 431,300 Aug 30 04:05 PM Kersten Dirk Director Aug 26 '24 Sale 45.30 89,497 4,054,408 630,964 Aug 28 04:05 PM Kersten Dirk Director Aug 27 '24 Sale 44.28 65,403 2,896,045 565,561 Aug 28 04:05 PM Kersten Dirk Director Aug 22 '24 Sale 45.82 95,321 4,368,083 805,549 Aug 26 04:05 PM Kersten Dirk Director Aug 23 '24 Sale 46.23 85,088 3,934,005 720,461 Aug 26 04:05 PM Kersten Dirk Director Aug 21 '24 Sale 46.78 135,763 6,350,605 900,870 Aug 22 04:05 PM Kersten Dirk Director Aug 20 '24 Sale 46.35 86,840 4,025,015 1,036,633 Aug 22 04:05 PM Forbion Capital Fund IV Cooper Affiliate Aug 21 '24 Proposed Sale 46.48 1,025,000 47,642,000 Aug 21 04:02 PM Scalzo Richard William SVP, Head of Finance & Admin. Aug 19 '24 Sale 45.12 2,752 124,174 111,022 Aug 20 04:28 PM McNeill Jonathan Chief Business Officer Aug 19 '24 Sale 45.12 2,705 122,054 132,106 Aug 20 04:27 PM Farwell Wildon Chief Medical Officer Aug 19 '24 Sale 45.12 2,321 104,727 143,222 Aug 20 04:27 PM HIGH SUSANNA GATTI Chief Operating Officer Aug 19 '24 Sale 45.12 2,910 131,304 145,882 Aug 20 04:26 PM Beskrovnaya Oxana Chief Scientific Officer Aug 19 '24 Sale 45.12 2,636 118,939 144,875 Aug 20 04:26 PM Kersten Dirk Director Aug 19 '24 Sale 45.82 126,032 5,774,365 1,123,473 Aug 20 04:05 PM Kersten Dirk Director Aug 16 '24 Sale 45.14 122,643 5,535,818 1,249,505 Aug 20 04:05 PM Farwell Wildon Officer Aug 19 '24 Proposed Sale 45.12 2,321 104,718 Aug 19 04:13 PM Scalzo Richard William Officer Aug 19 '24 Proposed Sale 45.12 2,752 124,163 Aug 19 04:12 PM
Index - P/E - EPS (ttm) -1.28 Insider Own 67.95% Shs Outstand 45.76M Perf Week -1.27%
Market Cap 40.90M Forward P/E - EPS next Y -0.67 Insider Trans 5.24% Shs Float 16.59M Perf Month -25.47%
Income -58.24M PEG - EPS next Q 0.19 Inst Own 13.83% Short Float 4.19% Perf Quarter -14.81%
Sales 6.34M P/S 6.45 EPS this Y 71.19% Inst Trans 18.42% Short Ratio 0.17 Perf Half Y -3.03%
Book/sh 0.38 P/B 2.05 EPS next Y -114.82% ROA -88.24% Short Interest 0.69M Perf Year 15.33%
Cash/sh 1.07 P/C 0.74 EPS next 5Y 17.37% ROE -214.02% 52W Range 0.58 - 1.93 Perf YTD -17.28%
Dividend Est. - P/FCF - EPS past 5Y -11.55% ROI -237.21% 52W High -59.07% Beta -0.28
Dividend TTM - Quick Ratio 2.21 Sales past 5Y 0.00% Gross Margin 72.70% 52W Low 36.21% ATR (14) 0.10
Dividend Ex-Date - Current Ratio 2.21 EPS Y/Y TTM 53.92% Oper. Margin -940.18% RSI (14) 43.67 Volatility 5.99% 10.82%
Employees 64 Debt/Eq 0.46 Sales Y/Y TTM - Profit Margin -918.05% Recom 1.33 Target Price 4.50
Option/Short No / Yes LT Debt/Eq 0.39 EPS Q/Q 68.41% Payout - Rel Volume 0.04 Prev Close 0.78
Sales Surprise -47.82% EPS Surprise 7.71% Sales Q/Q - Earnings Mar 11 BMO Avg Volume 4.06M Price 0.79
SMA20 -7.77% SMA50 -12.60% SMA200 -15.16% Trades
Volume 163,589 Change 0.77%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated H.C. Wainwright
Buy
$36
Nov-16-21 Initiated Raymond James
Outperform
$31
Nov-16-21 Initiated Morgan Stanley
Overweight
$32
Nov-16-21 Initiated Guggenheim
Buy
$40
Nov-16-21 Initiated Cowen
Outperform
Mar-11-25 08:45AM
07:30AM
Feb-24-25 04:30PM
Feb-13-25 04:17AM
(Pharmaceutical Technology) -12.84%
Feb-12-25 10:44AM
07:35AM
Loading…
07:35AM
07:33AM
Feb-03-25 04:30PM
Jan-22-25 09:00AM
Jan-21-25 05:05PM
Jan-17-25 04:30PM
Jan-10-25 05:00PM
Dec-19-24 07:30AM
Dec-16-24 07:30AM
Dec-09-24 09:55AM
04:30PM
Loading…
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
Oct-30-24 09:01AM
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
11:10AM
Loading…
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Frankenfield Christopher James Chief Financial Officer Jan 02 '25 Sale 0.98 6,954 6,841 12,421 Jan 03 04:15 PM Brennan Kevin M. SVP, FINANCE AND ACCOUNTING Jan 02 '25 Sale 0.98 1,803 1,774 3,197 Jan 03 04:15 PM GILEAD SCIENCES, INC. 10% Owner Dec 18 '24 Buy 1.04 1,759,978 1,830,377 9,105,451 Dec 19 04:19 PM GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM
Index RUT P/E - EPS (ttm) -0.96 Insider Own 52.86% Shs Outstand 44.73M Perf Week 2.04%
Market Cap 157.70M Forward P/E - EPS next Y -1.09 Insider Trans -4.05% Shs Float 21.24M Perf Month -2.23%
Income -39.20M PEG - EPS next Q -0.36 Inst Own 56.82% Short Float 7.64% Perf Quarter -69.16%
Sales 0.00M P/S - EPS this Y -47.12% Inst Trans 7.41% Short Ratio 2.67 Perf Half Y -74.07%
Book/sh 6.59 P/B 0.53 EPS next Y 4.79% ROA -13.36% Short Interest 1.62M Perf Year -61.58%
Cash/sh 6.57 P/C 0.53 EPS next 5Y -6.04% ROE -13.81% 52W Range 3.18 - 16.94 Perf YTD -65.99%
Dividend Est. - P/FCF - EPS past 5Y - ROI -13.18% 52W High -79.34% Beta 2.54
Dividend TTM - Quick Ratio 42.50 Sales past 5Y 0.00% Gross Margin - 52W Low 10.06% ATR (14) 0.21
Dividend Ex-Date - Current Ratio 42.50 EPS Y/Y TTM 9.55% Oper. Margin - RSI (14) 33.89 Volatility 3.01% 3.94%
Employees 30 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.20 Target Price 9.12
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -80.54% Payout - Rel Volume 0.75 Prev Close 3.55
Sales Surprise - EPS Surprise -13.17% Sales Q/Q - Earnings Nov 07 BMO Avg Volume 608.16K Price 3.50
SMA20 0.24% SMA50 -22.42% SMA200 -66.64% Trades
Volume 458,921 Change -1.41%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-12-25 Downgrade Morgan Stanley
Overweight → Equal-Weight
$20 → $5
Feb-11-25 Downgrade Raymond James
Outperform → Mkt Perform
Aug-09-24 Upgrade Morgan Stanley
Equal-Weight → Overweight
$12 → $20
Jun-18-24 Initiated Stifel
Buy
$23
Jun-07-24 Initiated Raymond James
Outperform
$18
Dec-16-22 Downgrade Jefferies
Buy → Hold
$30 → $3.60
Dec-15-22 Downgrade Morgan Stanley
Overweight → Equal-Weight
$5
Oct-10-22 Initiated Morgan Stanley
Overweight
$34
Oct-10-22 Initiated Jefferies
Buy
$30
Oct-10-22 Initiated Cowen
Outperform
Mar-04-25 09:35AM
Feb-14-25 12:00PM
09:35AM
Feb-12-25 04:41PM
Feb-11-25 07:00AM
06:38AM
Loading…
06:38AM
Feb-01-25 12:07AM
Nov-25-24 04:00PM
Nov-11-24 09:55AM
Nov-07-24 04:00PM
08:10AM
Sep-10-24 04:00PM
Aug-26-24 04:00PM
Aug-08-24 08:05AM
May-28-24 04:05PM
04:36PM
Loading…
May-20-24 04:36PM
May-15-24 12:52PM
08:05AM
May-10-24 07:02PM
Apr-15-24 07:00PM
Mar-28-24 08:30AM
Mar-26-24 09:02PM
01:53PM
08:05AM
Feb-26-24 04:00PM
Jan-04-24 08:00AM
Dec-29-23 12:00PM
Dec-08-23 01:05PM
Nov-09-23 09:30AM
08:30AM
08:30AM
Loading…
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
Jul-26-23 09:40AM
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
(American City Business Journals)
Dec-15-22 10:10AM
09:53AM
08:49AM
08:22AM
07:00AM
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
(Investor's Business Daily) -6.14%
Sep-19-22 04:10PM
Sep-15-22 11:41AM
07:58AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Conner Edward R. Chief Medical Officer Nov 08 '24 Option Exercise 4.20 2,117 8,891 2,117 Nov 12 05:08 PM Conner Edward R. Chief Medical Officer Nov 08 '24 Sale 15.00 2,117 31,755 0 Nov 12 05:08 PM BVF PARTNERS L P/IL See Explanation of Responses Oct 29 '24 Sale 14.30 1,000,000 14,300,000 176,692 Oct 31 05:53 PM Conner Edward R. Chief Medical Officer Oct 28 '24 Option Exercise 4.20 2,673 11,227 2,673 Oct 30 04:17 PM Conner Edward R. Chief Medical Officer Oct 28 '24 Sale 15.00 2,673 40,095 0 Oct 30 04:17 PM EDWARD CONNER Officer Oct 28 '24 Proposed Sale 13.15 4,790 62,988 Oct 28 04:37 PM Conner Edward R. Chief Medical Officer Sep 19 '24 Option Exercise 4.20 4,790 20,118 4,790 Sep 20 05:36 PM Conner Edward R. Chief Medical Officer Sep 19 '24 Sale 15.00 4,790 71,850 0 Sep 20 05:36 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Sep 18 '24 Option Exercise 4.20 503 2,113 503 Sep 20 05:35 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Sep 19 '24 Sale 14.29 9,497 135,685 0 Sep 20 05:35 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Sep 18 '24 Sale 14.00 503 7,042 0 Sep 20 05:35 PM EDWARD CONNER Officer Sep 19 '24 Proposed Sale 13.50 4,790 64,665 Sep 19 04:27 PM JULIE PERSON Officer Sep 18 '24 Proposed Sale 12.75 10,000 127,500 Sep 18 04:37 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Jun 26 '24 Option Exercise 4.20 10,000 42,000 10,000 Jun 28 04:51 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Jun 26 '24 Sale 12.46 10,000 124,569 0 Jun 28 04:51 PM Dittman Jennifer Chief Development Oper Officer Jun 07 '24 Sale 14.17 494 7,000 0 Jun 10 04:26 PM Dittman Jennifer Chief Development Oper Officer May 20 '24 Sale 14.00 1,042 14,588 0 May 22 04:36 PM Dittman Jennifer Chief Development Oper Officer May 16 '24 Sale 14.04 23,578 331,066 0 May 20 04:33 PM Holles Natalie C. CEO May 09 '24 Option Exercise 4.20 20,222 84,932 1,239,058 May 10 04:04 PM Holles Natalie C. CEO May 09 '24 Sale 12.18 20,222 246,300 1,218,836 May 10 04:04 PM Holles Natalie C. CEO Apr 11 '24 Option Exercise 4.20 13,558 56,944 1,232,394 Apr 15 04:14 PM Holles Natalie C. CEO Apr 11 '24 Sale 12.19 13,558 165,214 1,218,836 Apr 15 04:14 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Option Exercise 4.20 1,107 4,649 1,107 Apr 08 05:21 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Sale 10.00 1,107 11,070 0 Apr 08 05:21 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
